AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.
Identifieur interne : 001257 ( Main/Exploration ); précédent : 001256; suivant : 001258AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.
Auteurs : G. Hakobyan ; V. Vardanyan [Arménie]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
English descriptors
- Teeft :
- Accrual, Cohort, Corticosteroid therapy, Damage accrual, Disease activity, Erythematosus, Fetal wastage, Glucocorticoid, Hydroxychloroquine, Intravenous, Intravenous cyclophosphamide, Irreversible organ damage, Lupus, Lupus nephritis, Medical center, Oral prednisone, Pregnant women, Prospective study, Proteinuria, Rheumatoid arthritis, Santo tomas, Systemic lupus erythematosus, Tertiary hospitals.
Abstract
Background The use of the hydroxychloroquine(HCQ) in pregnancy is controversial. The current practice of discontinuing these medications because of pregnancy makes little sense as the half-life of these medications is so long. Patients with autoimmune diseases, especially with systemic lupus erythematosus (SLE) have increased fetal wastage and one of the factors known to contribute to this fetal wastage is disease activity. It is also known that discontinuing the HCQ can precipitate flares of disease in lupus patients. Mothers and their potential offspring are therefore at risk for flares of disease and pregnancy failure if these medications are discontinued because of pregnancy. Objectives To determine the safety for both mother and fetus of HCQ, in pregnant patients with SLE and rheumatoid arthritis (RA) who continued antimalarial drugs throughout pregnancy. Methods We studied 30 case histories of pregnant women (22 with SLE, and 8 - with RA), all of whom took hydroxychloroquine (Plaquenil) throughout pregnancy. All 30 pregnancies, resulted in 30 live births (18 full term and 12 preterm). Results No congenital abnormalities occurred and mean follow-up of 1 year (range 10-48 months) revealed no abnormalities in these children. Temporary discontinuation of HCQ for 1-2 months in 9 pregnancies precipitated a flare of disease (SLE or RA), documented both clinically and serologically, which required administration of glucocorticoids in relatively high doses. Conclusions It is safer to continue hydroxychloroquine rather than to discontinue this drug simply because of pregnancy. References Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001 Mar;77(905):157-65. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.2694
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B96
- to stream Istex, to step Curation: 000B96
- to stream Istex, to step Checkpoint: 000309
- to stream Main, to step Merge: 001258
- to stream Main, to step Curation: 001257
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.</title><author><name sortKey="Hakobyan, G" sort="Hakobyan, G" uniqKey="Hakobyan G" first="G." last="Hakobyan">G. Hakobyan</name></author><author><name sortKey="Vardanyan, V" sort="Vardanyan, V" uniqKey="Vardanyan V" first="V." last="Vardanyan">V. Vardanyan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5D7915023F974EE91CE65D8189F0FD5B267794D3</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.2694</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-ZP7QCS63-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B96</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B96</idno><idno type="wicri:Area/Istex/Curation">000B96</idno><idno type="wicri:Area/Istex/Checkpoint">000309</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000309</idno><idno type="wicri:doubleKey">0003-4967:2013:Hakobyan G:ab:safety:of</idno><idno type="wicri:Area/Main/Merge">001258</idno><idno type="wicri:Area/Main/Curation">001257</idno><idno type="wicri:Area/Main/Exploration">001257</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.</title><author><name sortKey="Hakobyan, G" sort="Hakobyan, G" uniqKey="Hakobyan G" first="G." last="Hakobyan">G. Hakobyan</name><affiliation></affiliation><affiliation><wicri:noCountry code="subField">Gavar</wicri:noCountry></affiliation></author><author><name sortKey="Vardanyan, V" sort="Vardanyan, V" uniqKey="Vardanyan V" first="V." last="Vardanyan">V. Vardanyan</name><affiliation wicri:level="1"><country xml:lang="fr">Arménie</country><wicri:regionArea>Yerevan State Medical University, Yerevan</wicri:regionArea><wicri:noRegion>Yerevan</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Arménie</country><wicri:regionArea>Yerevan State Medical University, Yerevan</wicri:regionArea><wicri:noRegion>Yerevan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A901">A901</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Accrual</term><term>Cohort</term><term>Corticosteroid therapy</term><term>Damage accrual</term><term>Disease activity</term><term>Erythematosus</term><term>Fetal wastage</term><term>Glucocorticoid</term><term>Hydroxychloroquine</term><term>Intravenous</term><term>Intravenous cyclophosphamide</term><term>Irreversible organ damage</term><term>Lupus</term><term>Lupus nephritis</term><term>Medical center</term><term>Oral prednisone</term><term>Pregnant women</term><term>Prospective study</term><term>Proteinuria</term><term>Rheumatoid arthritis</term><term>Santo tomas</term><term>Systemic lupus erythematosus</term><term>Tertiary hospitals</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background The use of the hydroxychloroquine(HCQ) in pregnancy is controversial. The current practice of discontinuing these medications because of pregnancy makes little sense as the half-life of these medications is so long. Patients with autoimmune diseases, especially with systemic lupus erythematosus (SLE) have increased fetal wastage and one of the factors known to contribute to this fetal wastage is disease activity. It is also known that discontinuing the HCQ can precipitate flares of disease in lupus patients. Mothers and their potential offspring are therefore at risk for flares of disease and pregnancy failure if these medications are discontinued because of pregnancy. Objectives To determine the safety for both mother and fetus of HCQ, in pregnant patients with SLE and rheumatoid arthritis (RA) who continued antimalarial drugs throughout pregnancy. Methods We studied 30 case histories of pregnant women (22 with SLE, and 8 - with RA), all of whom took hydroxychloroquine (Plaquenil) throughout pregnancy. All 30 pregnancies, resulted in 30 live births (18 full term and 12 preterm). Results No congenital abnormalities occurred and mean follow-up of 1 year (range 10-48 months) revealed no abnormalities in these children. Temporary discontinuation of HCQ for 1-2 months in 9 pregnancies precipitated a flare of disease (SLE or RA), documented both clinically and serologically, which required administration of glucocorticoids in relatively high doses. Conclusions It is safer to continue hydroxychloroquine rather than to discontinue this drug simply because of pregnancy. References Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001 Mar;77(905):157-65. Disclosure of Interest None Declared</div></front></TEI><affiliations><list><country><li>Arménie</li></country></list><tree><noCountry><name sortKey="Hakobyan, G" sort="Hakobyan, G" uniqKey="Hakobyan G" first="G." last="Hakobyan">G. Hakobyan</name></noCountry><country name="Arménie"><noRegion><name sortKey="Vardanyan, V" sort="Vardanyan, V" uniqKey="Vardanyan V" first="V." last="Vardanyan">V. Vardanyan</name></noRegion><name sortKey="Vardanyan, V" sort="Vardanyan, V" uniqKey="Vardanyan V" first="V." last="Vardanyan">V. Vardanyan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001257 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001257 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5D7915023F974EE91CE65D8189F0FD5B267794D3
|texte= AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.
}}
| This area was generated with Dilib version V0.6.33. |  |